Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

Blood (2025) 146 (Supplement 1): 569.

https://doi.org/10.1182/blood-2025-569

Published: 2025

Journal Articles

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Ana Marin Niebla, Eva Gine, Mariana Bastos-Oreiro, Amanda Perez, Alba Cabirta, Fatima De la Cruz Vicente, Marta Canelo Vilaseca, Ana Jiménez Ubieto, Sonia González De Villambrosia, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Pilar Gomez Prieto, Raul Cordoba, Ana Saus Carreres, Alejandro Martin Garcia-Sancho, Ana Maria Garcia-Noblejas Moya, Carlos Grande, Pablo Prieto Martínez, Concepción Nicolás, Antonio Gutierrez, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Maria Teresa Villalobos, Tomas García-Cerecedo, Rosalia Alonso Trillo, Eva Donato, Paola Villafuerte Gutiérrez, Daniel García Belmonte, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Juan-Manuel Sancho, Beatriz De La Cruz, Raja Prince-Eladnani, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2025-3592

Published: 2025

Journal Articles

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Mariana Bastos-Oreiro, Alba Cabirta, Amanda Perez, Ana Saus Carreres, Sonia González De Villambrosia, Marta Canelo, Ana Maria Garcia-Noblejas Moya, Beatriz De La Cruz Benito, Paola Villafuerte Gutiérrez, Fatima De la Cruz Vicente, Juan Carlos Caballero, Ana Jiménez-Ubieto, Daniel García Belmonte, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Alejandro Martin Garcia-Sancho, Carlos Grande, Concepción Nicolás, Antonio Gutierrez, Marina Gomez-Llobell, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Ainara Ferrero Campos, Rosalia Alonso Trillo, Eva Donato, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Pilar Gomez Prieto, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Raul Cordoba, Juan-Manuel Sancho, Eva Gine, Víctor Navarro Garces, Pau Abrisqueta, Ana Marin Niebla

Blood (2025) 146 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2025-3585

Published: 2025

Journal Articles

Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group

Blood (2025) 146 (Supplement 1): 472.

https://doi.org/10.1182/blood-2025-472

Published: 2025

Journal Articles

First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)

Blood (2025) 146 (Supplement 1): 3677.

https://doi.org/10.1182/blood-2025-3677

Published: 2025

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Blood (2023) 142 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2023-181628

Published: 2023

Journal Articles

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Blood (2021) 138 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2021-148361

Published: 2021

Journal Articles

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E. Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz Vicente, Dolores Caballero, Ranjana Advani, Raquel de Oña, Ana Marin Niebla, María José Terol, Domingo Domenech Eva, Nawal Bendris, Julie Mackey Ahsan, Mollie Leoni, Francine M. Foss

Blood (2021) 138 (Supplement 1): 621.

https://doi.org/10.1182/blood-2021-147279

Published: 2021

Journal Articles

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Eric D Jacobsen, MD, Won-Seog Kim, MD PhD, Francine M. Foss, MD, Ranjana H. Advani, MD, Jose Maria Roncero Vidal, MD, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, PhD, Raquel De Ona Navarrete, MD, Fátima de la Cruz Vicente, MD, Dolores Caballero, MD, Rufino Mondejar, PhD, Miguel A. Piris, PhD MD, Robert Curry, BA, MBA, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2018) 132 (Supplement 1): 2937.

https://doi.org/10.1182/blood-2018-99-116277

Published: 2018

Journal Articles

Role of PET/CT Assesment before Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma Patients

Fátima de la Cruz Vicente, MD, Maria Angeles Domiunguez Muñoz, MD, Estrella Carrillo Cruz, MD, José Francisco Márquez Malaver, Rocio Parody Porras, MD, Jose Francisco Falantes González, MD, Cristina Calderón Cabrera, MD, Olga Pérez López, MD, María Solé Rodríguez, MD, Jose González Campos, MD, María Isabel Montero Cuadrado, MD, María Luz Martino Galiana, MD, Jose Antonio Pérez-Simón, PhD, Ildefonso Espigado, PhD

Blood (2014) 124 (21): 3977.

https://doi.org/10.1182/blood.V124.21.3977.3977

Published: 2014

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Fátima de la Cruz Vicente, Estrella Carrillo Cruz, María Solé Rodríguez, Ana Marín Niebla, Eduardo Ríos Herranz, María Luz Martino Galiana, Jose Falantes González, Isabel Montero Cuadrado, Jose González Campos, Ildefonso Espigado Tocino, Jose A Pérez-Simón

Blood (2013) 122 (21): 5087.

https://doi.org/10.1182/blood.V122.21.5087.5087

Published: 2013

Journal Articles

The Role Of 18F-FDG PET/CT For Staging and Response Assessment To Chemotherapy In Marginal Zone Lymphoma.

Marta Ruiz Mercado, Estrella Carrillo Cruz, Fátima de la Cruz Vicente, Víctor A Marín-Oyaga, María Solé Rodríguez, Isabel Borrego-Dorado, Ildefonso Espigado Tocino, Ricardo Vázquez-Albertino, Jose Antonio Pérez-Simón

Blood (2013) 122 (21): 4328.

https://doi.org/10.1182/blood.V122.21.4328.4328

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group

First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Role of PET/CT Assesment before Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma Patients

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

The Role Of 18F-FDG PET/CT For Staging and Response Assessment To Chemotherapy In Marginal Zone Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only